Aarti Pharmalabs announces strong FY25 performance and 6th annual general meeting

Aarti Pharmalabs Limited announced its 6th Annual General Meeting (AGM) will be held on Monday, September 22, 2025. The company reported a robust financial year, with consolidated operational revenue increasing by 14.3% year-over-year to INR 2,115 Crs. Profit after Tax (PAT) also saw a substantial rise of 25.6% to INR 272 Crs, with the PAT margin expanding by 117 basis points to 12.88%.

The company's strategic investments are yielding results, with 391 Crs invested in growth projects for FY 2024-25. Aarti Pharmalabs projects an EBITDA growth of approximately 12-15% for FY 2025-26, driven by higher-margin products and improved process efficiencies. Additionally, the company's credit rating was upgraded to CRISIL AA-/Stable, reflecting its strong financial profile and market position.

Shareholders will receive a total dividend of 5 per equity share for FY 2024-25, comprising an interim dividend of 2.50 and a recommended final dividend of 2.50. The company’s net debt to equity ratio remained conservative at 0.19 as of March 31, 2025.